Highlander Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Highlander Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$56	Hold	4	–	–	﹤0.01%	926
2023 Q4	$26	Hold	4	–	–	﹤0.01%	969
2023 Q3	$0	Buy	+4	New	+$22	﹤0.01%	922
2023 Q2	–	Sell	-4	Closed	–	–	683
2023 Q1	$0	Hold	4	–	–	﹤0.01%	668
2022 Q4	$0	Hold	4	–	–	﹤0.01%	634
2022 Q3	$0	Hold	4	–	–	﹤0.01%	627
2022 Q2	$0	Hold	4	–	–	﹤0.01%	637
2022 Q1	$0	Hold	4	–	–	﹤0.01%	618
2021 Q4	$0	Hold	4	–	–	﹤0.01%	601
2021 Q3	$0	Hold	4	–	–	﹤0.01%	601
2021 Q2	$0	Hold	4	–	–	﹤0.01%	614
2021 Q1	$0	Hold	4	–	–	﹤0.01%	624
2020 Q4	$0	Hold	4	–	–	﹤0.01%	615
2020 Q3	$1K	Hold	4	–	–	﹤0.01%	579
2020 Q2	$1K	Hold	4	–	–	﹤0.01%	575
2020 Q1	$0	Buy	+4	New	+$247	﹤0.01%	640

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Highlander Capital Management's INO Position: Q1 2024 in Review

Highlander Capital Management held its Inovio Pharmaceuticals (INO) position steady in Q1 2024 at 4 shares worth $56. The position accounts for ﹤0.01% of the portfolio, ranked #926.

Highlander Capital Management first reported a position in INO in Q1 2020 and has held it in 16 quarters since. The position peaked at $1K in Q3 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

Highlander Capital Management held 4 shares of Inovio Pharmaceuticals worth $56 as of Q1 2024.
Highlander Capital Management left its Inovio Pharmaceuticals share count unchanged in Q1 2024.
Inovio Pharmaceuticals made up ﹤0.01% of Highlander Capital Management's portfolio in Q1 2024, its #926 holding.
Highlander Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2020 and has held it in 16 quarters since.
Highlander Capital Management's Inovio Pharmaceuticals position peaked at $1K in Q3 2020.
89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.